New advances in amblyopia therapy I: Binocular therapies and pharmacologic augmentation [PDF]
, 2018 Amblyopia therapy options have traditionally been limited to penalisation of the non-amblyopic eye with either patching or pharmaceutical penalisation. Solid evidence, mostly from the Pediatric Eye Disease Investigator Group, has validated both number of
Culican, Susan M, Kraus, Courtney L
core +2 more sources
Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis [PDF]
, 2010 Background/Aims: Increasing evidence suggests that elevated levels of homocysteine (Hcy) and methylmalonate (MMA) may be involved in the pathogenesis of neurodegenerative diseases. Methods: The urine levels of MMA and serum levels of Hcy as well as folic
Bötzel, Kai +4 more
core +1 more source
Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
ACS Sensors, 2019 Levodopa is the most effective medication for treating Parkinson's disease (PD). However, because dose optimization is currently based on patients' report of symptoms, which are difficult for patients to describe, the management of PD is challenging.
K. Y. Goud +6 more
semanticscholar +1 more source
Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease
New England Journal of Medicine, 2019 BACKGROUND Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease‐modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be ...
C. V. Verschuur +13 more
semanticscholar +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Annals of Neurology, 2018 Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal ...
A. Espay +9 more
semanticscholar +1 more source
Extended Timed Up and Go assessment as a clinical indicator of cognitive state in Parkinson\u27s disease [PDF]
, 2017 Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) severity and cognitive impairment. Methods: Eighty-seven participants with
Anderton, R +7 more
core +2 more sources
EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
Movement Disorders, 2019 Real‐life observational report of clinical efficacy of bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD).
H. Dafsari +23 more
semanticscholar +1 more source